# AbbVie expands biologics manufacturing capacity in Singapore with $223M investment

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility in Tuas Biomedical Park, adding 24,000 liters of biologics drug-substance capacity and over 100 jobs. The expansion is expected to become operational in 2026.

- Type: Expansion
- Announced: 2024-01-25
- Where: Tuas Biomedical Park, Singapore, Singapore
- Value: $223.0M
- Jobs: 100
- Starts operating: 2026
- Status: under construction
- Capacity: 24,000 liters of biologics drug-substance capacity
- Products: biologics drug substances
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [AbbVie](https://endata.com/companies/29401.md)

## Sources

- [news.abbvie.com](https://news.abbvie.com/2024-01-26-AbbVie-Expands-Biologics-Manufacturing-Capacity-with-a-223-Million-Investment-in-Singapore-Manufacturing-Site), 2024-01-25: "This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.